Search Results - christian+hinrichs

9 Results

Sort By:

Tiered Screening of Therapeutic TCRs for Identification of Autoimmune Cross-Reactivity

Summary: The National Cancer Institute seeks research co-development partners and/or licensees for a standardized method of detecting T-cell receptor (TCR) cross-reactivity as a means of proving safety and efficacy in preclinical evaluations ahead of clinical trials. Description of Technology: TCR-based therapies targeting cancer-associated antigens...

Published: 4/8/2024 | Inventor(s): Kazusa Ishii, Christian Hinrichs, John Davies

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics

T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors

Abstract: Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely...

Published: 4/8/2024 | Inventor(s): Sanja Stevanovic, Christian Hinrichs

Keywords(s): CT83, Immunotherapy, Kita-Kyushu Lung Cancer Antigen, KK-LC-1, T-Cell Receptor, TCR, Testis

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain

Abstract: Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient’s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases. However, a number of obstacles to the overall success...

Published: 4/8/2024 | Inventor(s): Paul Love, Guillaume Gaud, Christian Hinrichs, John Davies

Keywords(s): CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

: Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes

Abstract: Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Zhijian Duan, Christian Hinrichs

Keywords(s): adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein

Abstract: Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain – an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently,...

Published: 4/8/2024 | Inventor(s): Christian Hinrichs, Steven Rosenberg

Keywords(s): act, adoptive cell therapy, Cervical cancer, E7, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias

Abstract: CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include...

Published: 8/14/2024 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias

Abstract: CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have...

Published: 8/14/2024 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein

Published: 4/8/2024 | Inventor(s): Christian Hinrichs, Steven Rosenberg

Keywords(s): act, adoptive cell therapy, Cervical cancer, E6, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy

Abstract: Interleukin-15 (IL-15) and IL-21 have been reported to support the function of anti-tumor T cells. However, their use in the clinic has been constrained, in part, by dose-limiting toxicity and the need for repeated administration. To overcome these limitations, researchers in the National Cancer Institute (NCI) Experimental Transplantation...

Published: 4/8/2024 | Inventor(s): Christian Hinrichs, Benjamin Jin

Keywords(s): act, adoptive cell therapy, CANCER, CAR, chimeric antigen receptor, Hinrichs, IL-15, IL-21, INTERLEUKIN-15, Interleukin-21, T Cells

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing